Value of a revised procainamide test in the Wolff-Parkinson-White syndrome.
Identifieur interne : 001250 ( Ncbi/Checkpoint ); précédent : 001249; suivant : 001251Value of a revised procainamide test in the Wolff-Parkinson-White syndrome.
Auteurs : K A Boahene [Canada] ; G J Klein ; A D Sharma ; R. Yee ; O. FujimuraSource :
- The American journal of cardiology [ 0002-9149 ] ; 1990.
English descriptors
- KwdEn :
- Adolescent, Adult, Aged, Atrial Fibrillation (physiopathology), Dose-Response Relationship, Drug, Electrocardiography, Evaluation Studies as Topic, Female, Heart Conduction System (physiopathology), Heart Function Tests (standards), Humans, Male, Middle Aged, Procainamide, Refractory Period, Electrophysiological, Wolff-Parkinson-White Syndrome (diagnosis), Wolff-Parkinson-White Syndrome (physiopathology).
- MESH :
- chemical : Procainamide.
- diagnosis : Wolff-Parkinson-White Syndrome.
- physiopathology : Atrial Fibrillation, Heart Conduction System, Wolff-Parkinson-White Syndrome.
- standards : Heart Function Tests.
- Adolescent, Adult, Aged, Dose-Response Relationship, Drug, Electrocardiography, Evaluation Studies as Topic, Female, Humans, Male, Middle Aged, Refractory Period, Electrophysiological.
Abstract
A shortest preexcited RR interval less than 250 ms during atrial fibrillation identifies the patient with Wolff-Parkinson-White syndrome potentially at risk for ventricular fibrillation. Loss of preexcitation after infusion of up to 10 mg/kg of procainamide during sinus rhythm has been reported to correlate with a slow ventricular response during atrial fibrillation and has been proposed as a noninvasive test to establish risk of sudden death in these patients. Others have failed to establish this relation and have questioned the usefulness of the procainamide test. Such conflicting results were hypothesized to be a result of differing dosages and methodology. Consequently, this study tested the effect of incremental doses of procainamide (to a cumulative dose of 1 g) on the anterograde effective refractory period of the accessory pathway and related the reliability of the procainamide test to the dose at which preexcitation was lost. The effect of procainamide on the anterograde effective refractory period of the accessory pathway was dose dependent; patients who lost preexcitation had a steeper dose-response curve. Loss of preexcitation by a cumulative dose of 550 mg provided the best balance for sensitivity (60%) and specificity (89%) in identifying patients with preexcited shortest RR greater than 250 ms. Specificity fell steeply after this dosage and higher doses were not useful. The diagnostic accuracy of the procainamide test is critically related to dosage and method of infusion.
PubMed: 2296888
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001B85
- to stream PubMed, to step Curation: 001B85
- to stream PubMed, to step Checkpoint: 001B85
- to stream Ncbi, to step Merge: 001250
- to stream Ncbi, to step Curation: 001250
Links to Exploration step
pubmed:2296888Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Value of a revised procainamide test in the Wolff-Parkinson-White syndrome.</title><author><name sortKey="Boahene, K A" sort="Boahene, K A" uniqKey="Boahene K" first="K A" last="Boahene">K A Boahene</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, University Hospital, London, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medicine, University Hospital, London, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Klein, G J" sort="Klein, G J" uniqKey="Klein G" first="G J" last="Klein">G J Klein</name></author><author><name sortKey="Sharma, A D" sort="Sharma, A D" uniqKey="Sharma A" first="A D" last="Sharma">A D Sharma</name></author><author><name sortKey="Yee, R" sort="Yee, R" uniqKey="Yee R" first="R" last="Yee">R. Yee</name></author><author><name sortKey="Fujimura, O" sort="Fujimura, O" uniqKey="Fujimura O" first="O" last="Fujimura">O. Fujimura</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1990">1990</date><idno type="RBID">pubmed:2296888</idno><idno type="pmid">2296888</idno><idno type="wicri:Area/PubMed/Corpus">001B85</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001B85</idno><idno type="wicri:Area/PubMed/Curation">001B85</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001B85</idno><idno type="wicri:Area/PubMed/Checkpoint">001B85</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001B85</idno><idno type="wicri:Area/Ncbi/Merge">001250</idno><idno type="wicri:Area/Ncbi/Curation">001250</idno><idno type="wicri:Area/Ncbi/Checkpoint">001250</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Value of a revised procainamide test in the Wolff-Parkinson-White syndrome.</title><author><name sortKey="Boahene, K A" sort="Boahene, K A" uniqKey="Boahene K" first="K A" last="Boahene">K A Boahene</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, University Hospital, London, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medicine, University Hospital, London, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Klein, G J" sort="Klein, G J" uniqKey="Klein G" first="G J" last="Klein">G J Klein</name></author><author><name sortKey="Sharma, A D" sort="Sharma, A D" uniqKey="Sharma A" first="A D" last="Sharma">A D Sharma</name></author><author><name sortKey="Yee, R" sort="Yee, R" uniqKey="Yee R" first="R" last="Yee">R. Yee</name></author><author><name sortKey="Fujimura, O" sort="Fujimura, O" uniqKey="Fujimura O" first="O" last="Fujimura">O. Fujimura</name></author></analytic><series><title level="j">The American journal of cardiology</title><idno type="ISSN">0002-9149</idno><imprint><date when="1990" type="published">1990</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Atrial Fibrillation (physiopathology)</term><term>Dose-Response Relationship, Drug</term><term>Electrocardiography</term><term>Evaluation Studies as Topic</term><term>Female</term><term>Heart Conduction System (physiopathology)</term><term>Heart Function Tests (standards)</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Procainamide</term><term>Refractory Period, Electrophysiological</term><term>Wolff-Parkinson-White Syndrome (diagnosis)</term><term>Wolff-Parkinson-White Syndrome (physiopathology)</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Procainamide</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Wolff-Parkinson-White Syndrome</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Atrial Fibrillation</term><term>Heart Conduction System</term><term>Wolff-Parkinson-White Syndrome</term></keywords><keywords scheme="MESH" qualifier="standards" xml:lang="en"><term>Heart Function Tests</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Dose-Response Relationship, Drug</term><term>Electrocardiography</term><term>Evaluation Studies as Topic</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Refractory Period, Electrophysiological</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A shortest preexcited RR interval less than 250 ms during atrial fibrillation identifies the patient with Wolff-Parkinson-White syndrome potentially at risk for ventricular fibrillation. Loss of preexcitation after infusion of up to 10 mg/kg of procainamide during sinus rhythm has been reported to correlate with a slow ventricular response during atrial fibrillation and has been proposed as a noninvasive test to establish risk of sudden death in these patients. Others have failed to establish this relation and have questioned the usefulness of the procainamide test. Such conflicting results were hypothesized to be a result of differing dosages and methodology. Consequently, this study tested the effect of incremental doses of procainamide (to a cumulative dose of 1 g) on the anterograde effective refractory period of the accessory pathway and related the reliability of the procainamide test to the dose at which preexcitation was lost. The effect of procainamide on the anterograde effective refractory period of the accessory pathway was dose dependent; patients who lost preexcitation had a steeper dose-response curve. Loss of preexcitation by a cumulative dose of 550 mg provided the best balance for sensitivity (60%) and specificity (89%) in identifying patients with preexcited shortest RR greater than 250 ms. Specificity fell steeply after this dosage and higher doses were not useful. The diagnostic accuracy of the procainamide test is critically related to dosage and method of infusion.</div></front></TEI><affiliations><list><country><li>Canada</li></country></list><tree><noCountry><name sortKey="Fujimura, O" sort="Fujimura, O" uniqKey="Fujimura O" first="O" last="Fujimura">O. Fujimura</name><name sortKey="Klein, G J" sort="Klein, G J" uniqKey="Klein G" first="G J" last="Klein">G J Klein</name><name sortKey="Sharma, A D" sort="Sharma, A D" uniqKey="Sharma A" first="A D" last="Sharma">A D Sharma</name><name sortKey="Yee, R" sort="Yee, R" uniqKey="Yee R" first="R" last="Yee">R. Yee</name></noCountry><country name="Canada"><noRegion><name sortKey="Boahene, K A" sort="Boahene, K A" uniqKey="Boahene K" first="K A" last="Boahene">K A Boahene</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Ncbi/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001250 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd -nk 001250 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Ncbi
|étape= Checkpoint
|type= RBID
|clé= pubmed:2296888
|texte= Value of a revised procainamide test in the Wolff-Parkinson-White syndrome.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/RBID.i -Sk "pubmed:2296888" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |